Hartman joined ConMed’s board in March after an ugly proxy war.
The proxy battle also led to the retirement of founder Gene Corasanti and the resignation of CEO, president and director Joseph Corasanti. ConMed named Hartman interim CEO in July, keeping his seat on the board but relinquishing a role on its audit committee.
In the run-up to a September shareholder’s meeting, a bitter war for control of the board at ConMed saw the company vie with Voce Capital Partners for control. In August Voce rebuffed a ConMed offer that would have admitted to the board a Voce nominee,Accuray (NSDQ:ARAY) president & CEO Joshua Levine; ConMed then nominated its own slate for reelection: Hartman, Lande and Tryniski, plus Haemonetics (NYSE:HAE) CEO Brian Concannon, Dirk Kuyper, Charles Farkas, Jo Ann Golden and Stephen Mandia.
Shareholders rejected the Voce slate at the Sept. 10 meeting, according to a regulator filing, electing the 8 candidates nominated by ConMed.
ConMed shares are up about 4.7% since the company posted better-than-expected 3rd-quarter earnings despite a 65% profit slide. ConMed reported profits of $2.0 million, or 7¢ per share, on a sales decline of 2.4% to $175.0 million for the 3 months ended Sept. 30. Adjusted to exclude 1-time items, earnings per share were 44¢, a nickel abobe Wall Street’s forecast and 10% above adjusted EPS in Q3 2013.
Acelity promotes Busenlehner to principal finance officer
Acelity said it promoted controller Brian Busenlehner to be its principal financial officer and to be interim CFO of its Kinetic Concepts Inc., LifeCell and Systagenix Wound Management businesses.
Covidien M&A advisor Carnell wins corner office at BSD Medical
BSD Medical said it named Clint Carnell, an advisor to Covidien (NYSE:COV) over its $43 billion merger with Medtronic (NYSE:MDT), to be its new president & CEO. Carnell succeeds Butch Wolcott, who announced his impending retirement last April.
TransEnterix COO Mueller steps down
TransEnterix said its COO, Richard Mueller, resigned effective Nov. 7. Mueller was named chief technology office in 2011 and moved to COO in January 2013.